Recent studies have verified that Galectin-1 [73], [74] and other proteins identified in -BD11 ECM, e.g. aminopeptidase-N [75] annexin-A2 [76] or nucleolin [77], can serve as tumour targets, with evidence that combined targeting of perivascular and endothelial cells can enhance anti-tumour treatment [78]. This evidence concerns the gene LGALS1 and neoplasm.